---
document_datetime: 2023-09-21 20:05:03
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/mvabea-epar-all-authorised-presentations_en.pdf
document_name: mvabea-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6693498
conversion_datetime: 2025-12-24 09:17:11.946935
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|--------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/20/1445/001 | MVABEA            | --¹        | Suspension for injection | Intramuscular use         | Vial (glass)          | 0.5 mL                    | 20 vials    |

--¹ One dose (0.5 mL) contains:

Modified Vaccinia Ankara Bavarian Nordic Virus encoding the:

Zaire ebolavirus (EBOV) Mayinga variant glycoprotein (GP) Sudan ebolavirus Gulu variant GP Taï Forest ebolavirus nucleoprotein Marburg marburgvirus Musoke variant GP

Not less than 0.7 x 10 8 infectious units (Inf.U)